Robert A. Kramer

4.6k total citations · 1 hit paper
88 papers, 3.5k citations indexed

About

Robert A. Kramer is a scholar working on Molecular Biology, Oncology and Electrical and Electronic Engineering. According to data from OpenAlex, Robert A. Kramer has authored 88 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 18 papers in Oncology and 16 papers in Electrical and Electronic Engineering. Recurrent topics in Robert A. Kramer's work include Frequency Control in Power Systems (8 papers), Power System Optimization and Stability (8 papers) and Angiogenesis and VEGF in Cancer (6 papers). Robert A. Kramer is often cited by papers focused on Frequency Control in Power Systems (8 papers), Power System Optimization and Stability (8 papers) and Angiogenesis and VEGF in Cancer (6 papers). Robert A. Kramer collaborates with scholars based in United States, Germany and Thailand. Robert A. Kramer's co-authors include Craig R. Fairchild, George Kim, Gregory D. Vite, Francis Y. F. Lee, William C. Rose, R. M. Borzilleri, Goeun Choi, J. M. Woodall, Soong‐Hoon Kim and Byron H. Long and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Robert A. Kramer

81 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective STING stimulation in dendritic cells primes antitumor T cell responses

2023 103 citations Aurore Bochnakian, Caroline Hoffmann et al. Science Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert A. Kramer United States	29	1.5k	999	715	381	311	88	3.5k
Alakananda Basu United States	36	3.3k 2.1×	1.4k 1.4×	606 0.8×	386 1.0×	177 0.6×	109	5.1k
James M. Gallo United States	42	1.9k 1.2×	1.3k 1.3×	517 0.7×	322 0.8×	161 0.5×	154	5.0k
Andrew M. Stern United States	32	1.6k 1.0×	644 0.6×	359 0.5×	451 1.2×	258 0.8×	89	3.3k
Massimo Zucchetti Italy	40	1.8k 1.2×	1.9k 1.9×	421 0.6×	250 0.7×	417 1.3×	170	4.8k
Giovanna Damia Italy	39	2.7k 1.8×	1.7k 1.7×	858 1.2×	276 0.7×	181 0.6×	172	4.8k
Hirofumi Nakano Japan	26	1.6k 1.1×	637 0.6×	242 0.3×	434 1.1×	204 0.7×	140	3.1k
Shin‐ichi Akiyama Japan	41	2.7k 1.7×	2.2k 2.2×	1.1k 1.6×	321 0.8×	221 0.7×	194	5.3k
Akulapalli Sudhakar United States	20	2.2k 1.4×	654 0.7×	927 1.3×	145 0.4×	172 0.6×	29	4.0k
Ralph E. Parchment United States	37	2.3k 1.5×	1.8k 1.8×	729 1.0×	209 0.5×	220 0.7×	184	4.4k
Jörg Stürzebecher Germany	35	1.7k 1.1×	742 0.7×	718 1.0×	611 1.6×	1.2k 3.7×	130	4.2k

Countries citing papers authored by Robert A. Kramer

Since Specialization

Citations

This map shows the geographic impact of Robert A. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Kramer more than expected).

Fields of papers citing papers by Robert A. Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Kramer. The network helps show where Robert A. Kramer may publish in the future.

Co-authorship network of co-authors of Robert A. Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Kramer. A scholar is included among the top collaborators of Robert A. Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Kramer. Robert A. Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kramer, Robert A., et al.. (2025). Design of a Fast-Switchable Three-Stage GaN Doherty PA for High DC-to-RF Efficiency. 1905–1908.

Kramer, Robert A., et al.. (2025). Fast-Switchable 3.6 GHz GaN Doherty Power Amplifier for Energy-Efficient Non-Continuous Transmission of 256-QAM Signals. 1095–1098. 1 indexed citations

Fong, Lawrence, Mohamad A. Salkeni, Anthony B. El-Khoueiry, et al.. (2024). ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e14681–e14681. 1 indexed citations

Bochnakian, Aurore, Caroline Hoffmann, Philémon Sirven, et al.. (2023). Selective STING stimulation in dendritic cells primes antitumor T cell responses. Science Immunology. 8(79). eabn6612–eabn6612. 103 indexed citations breakdown →

Subudhi, Sumit K., Gerald S. Falchook, Mohamad A. Salkeni, et al.. (2023). 759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors. SHILAP Revista de lepidopterología. A855–A855.

Attar, Ricardo M., Maria Jure–Kunkel, Aaron Balog, et al.. (2009). Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer. Cancer Research. 69(16). 6522–6530. 38 indexed citations

Carboni, Joan M., Mark D. Wittman, Zheng Yang, et al.. (2009). BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Molecular Cancer Therapeutics. 8(12). 3341–3349. 218 indexed citations

Lee, Francis Y. F., Richard Smykla, Kathy Johnston, et al.. (2008). Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemotherapy and Pharmacology. 63(2). 201–212. 83 indexed citations

Lee, Francis Y. F., R. M. Borzilleri, Craig R. Fairchild, et al.. (2008). Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemotherapy and Pharmacology. 63(1). 157–166. 88 indexed citations

10.

Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations

11.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2005). Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemotherapy and Pharmacology. 56(5). 455–464. 66 indexed citations

12.

Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations

13.

Barrientos, Laura G., Miguel Llinás, Melanie E. DeFord, et al.. (1998). Selective Inhibition by Kringle 5 of Human Plasminogen on Endothelial Cell Migration, an Important Process in Angiogenesis. Biochemical and Biophysical Research Communications. 247(2). 414–419. 78 indexed citations

14.

Kramer, Robert A., et al.. (1993). Modulation of MDR‐1 expression by a H‐ras oncogene in a human colon carcinoma cell line. International Journal of Cancer. 54(2). 275–281. 7 indexed citations

15.

Hurwitz, Selwyn J., C. Norman Coleman, Nancy Riese, et al.. (1992). Distribution of etanidzole into human brain tumors: Implications for treating high grade gliomas. International Journal of Radiation Oncology*Biology*Physics. 22(3). 573–576. 10 indexed citations

16.

Nakagawa, Yoshio & Robert A. Kramer. (1989). Nephrotoxicity of 5-(N-phenylcarboxamido)-2-thiobarbituric acid in the Fischer 344 rat. Cancer Chemotherapy and Pharmacology. 25(2). 109–113. 3 indexed citations

17.

Coleman, C. Norman, Edward A. Bump, & Robert A. Kramer. (1988). Chemical modifiers of cancer treatment.. Journal of Clinical Oncology. 6(4). 709–733. 94 indexed citations

18.

Kramer, Robert A., Hildegard M. Schuller, Adaline C. Smith, & M R Boyd. (1985). Effects of buthionine sulfoximine on the nephrotoxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU).. Journal of Pharmacology and Experimental Therapeutics. 234(2). 498–506. 24 indexed citations

19.

Kramer, Robert A. & M R Boyd. (1983). Nephrotoxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU) in the Fischer 344 rat.. Journal of Pharmacology and Experimental Therapeutics. 227(2). 409–414. 7 indexed citations

20.

Medearis, Donald N. & Robert A. Kramer. (1959). Exanthem associated with Echo virus type 18 viremia. The Journal of Pediatrics. 55(3). 367–373. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact